1. Alzheimer’s Association. “Tau.” Updated October 2021. https://www.alz.org/media/Documents/alzheimers-dementia-tau-ts. pdf.
2. Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018 Jul;14(7):399-415.
3. Congdon EE, Ji C, Tetlow AM, et al. Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol. 2023 Dec;19(12):715-736.
4. Horie K, Barthélemy NR, Sato C, et al. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease. Brain. 2021 Mar 3;144(2):515-527.
5. Frontzkowski L, et al. Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading. Nat Commun. 2022 Aug 20;13(1):4899.
6. Wesseling H, et al. Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease. Cell. 2020 Dec 10;183(6):1699-1713.e13.
7. Boccalini C, et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Alzheimers Dement. 2024 Jan;20(1):221-233.
8. Dolan P, et al. Microtubule Binding Region (MTBR)-Specific Antibody PRX005 Prevents Pathological Tau Progression via Blockade of Neuronal Internalization. Oral presentation at AD/PD 2021; March 9-14, 2021; Virtual. Partnership with BMS.